X
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): TOTUM•854
Therapeutic Area: Cardiology/Vascular Diseases Product Name: TOTUM•854
Highest Development Status: Phase II/ Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: University of Avignon
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 12, 2021
Details:
The results, obtained in vivo on models predictive of hypertension in humans, showed that TOTUM•854 is effective in preventing hypertension.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): TOTUM-854
Therapeutic Area: Cardiology/Vascular Diseases Product Name: TOTUM-854
Highest Development Status: Phase II/ Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: University of Avignon
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 08, 2021
Details:
Preclinical results with the active substance TOTUM-854 on arterial hypertension, obtained through work undertaken as part of an academic partnership with Avignon University’s Laboratoire de Pharm-Ecologie Cardiovasculaire (LAPEC) as well as at the Riom R&D platform.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
